Anti-Angiogenesis Strategies in Cancer Therapies

Dr. Mousa came to Albany College of Pharmacy and Health Sciences in 2002 following a career of more than 17 years as a principal research scientist at DuPont Pharmaceuticals Co. Among Dr. Mousa's professional accomplishments are his contributions to many patents – he holds more than 250 U.S. and international patents – and to the discovery and development of novel anti-platelet, anti-thrombotic therapies, non-invasive myocardial perfusion and thrombus imaging agents. Dr. Mousa serves on the editorial boards and as a reviewer for a number of scientific and medical journals, including Journal of Pharmaceutical Sciences, Frontiers in Molecular Neuroscience, Clinical and Applied Thrombosis/Hemostasis, Applied Microbiology and Biotechnology, and PLoS Computational Biology.Dr. Davis directs a group of scientists who have defined molecular mechanisms for many non-genomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. He has 5 patents issued and 25 US and international applications pending. Dr. Davis is a US Faculty Head in Endocrinology of the Faculty of 1000 Medicine and a member of the Endocrine Society, American Thyroid Association, American Society of Biochemistry and Molecular Biology, American Diabetes Association, American Association for Cancer Research and a Fellow of the American College of Physicians.

"...a comprehensive overview of all aspects of angiogenesis. The assessment of FDA-approved antiangiogenesis agents in cancer therapy and new applications of nanotechnology in antiangiogenesis interventions are very valuable to the field. Score: 98 - 5 Stars!" --Doody's

• 1. Role of Angiogenesis and lymphogenesis in Cancer (tumor growth, Invasion, metastasis2. Role of Angiogenesis and anti-angiogenesis in hematological malignancies (acute / chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms)3. The interface between Thrombosis-Inflammation and Angiogenesis4. Micro RNA and Angiogenesis modulation5. Preclinical discovery and development of different Pharmacological anti-angiogenesis agents6. Differences among different anti-angiogenesis strategies (Mechanisms of actions)7. Naturally Occurring Anti-angiogenesis8. Clinical trials with anti-angiogenesis agents: Approved agents9. Angiogenesis Biomarkers and Impact on personalized management10. Efficacy of Anti-VEGF therapy in cancer11. Nanotechnology in enhancing the utility of anti-angiogenesis agents – Combinations with other anti-cancer agents12. Multi-targeted anti-angiogenesis therapy in cancer13. Combination of anti-angiogenesis and chemotherapeutics14. Nanotechnology in enhancing the utility of anti-angiogenesis agents – Combinations with other anti-cancer agents15. Nano-targeted anti-angiogenesis agents in cancer detection16. Future Directions